- Adds clinical and preclinical immunology assets to pipeline, including potentially differentiated thyroid eye disease therapeutics
- Led by the IL-17A inhibitor izokibep, ACELYRIN now has a strong portfolio of immunology programs, including late-stage clinical trials in multiple indications.
Los Angeles, January 5, 2023 /PRNewswire/ — ACELYRIN, INC., a late-stage clinical biopharmaceutical company focused on accelerating the development and delivery of innovative medicines in immunology, today develops therapeutics for autoimmune and inflammatory diseases Announced the acquisition of ValenzaBio, a privately held company. Full stock trading. The acquisition of ValenzaBio adds multiple drugs to ACELYRIN’s strong immunology pipeline led by izokibep, a small therapeutic protein inhibitor of interleukin-17A (IL-17A) designed to overcome the limitations of monoclonal antibodies. Clinical and preclinical development programs are added.
“ACELYRIN has been developed to identify, acquire, and accelerate the development and delivery of therapeutics that have the potential to provide clinically meaningful and differentiated benefits to patients based on the science of molecular targets or properties. It was founded a little over a year ago.” xiao li ling, MD, PhD, Founder and CEO of ACELYRIN. “Previously shared phase 2 psoriatic arthritis data support our hypothesis that the characteristics of isokibep may lead to different patient outcomes compared to current treatment options, suggesting that suppurative Results reported separately today for hidradenitis provide data for a second indication that further supports that hypothesis. We believe these programs may similarly offer clinically meaningful and differentiated benefits compared to current treatment options.”
The acquisition of ValenzaBio adds several additional assets to the ACELYRIN portfolio, including:
- Lonigtamab (VB-421) is a subcutaneous anti-IGF-1R currently being evaluated in a Phase 1 trial in thyroid eye disease. $4 billion Estimated Market Opportunity – Potential impact on efficacy, safety and dosing benefits for patients.
- VB-517 is a pre-IND anti-c-KIT being investigated as a treatment option for chronic urticaria, $2.5 billion Estimated Market Opportunity.
“Since ValenzaBio was founded in 2019, our team has collaborated to identify and develop therapeutic candidates for a variety of underserved indications in a capital efficient manner. John Doe, MD, MBA, Chairman of the Board of ValenzaBio. “I have long admired Shao-Lee and her colleagues at ACELYRIN and firmly believe they are best suited to further develop these immunological assets and transform the way these diseases are treated. This acquisition by ACELYRIN drives value creation for ValenzaBio’s shareholders and the patients we all strive to serve.”
With the acquisition of ValenzaBio, Dr. Doux will join ACELYRIN’s Board of Directors. Dr. Doux is a Palo Alto Investors analyst and board certified dermatologist.
“We are excited to execute this transformative acquisition as we continue to grow Aserine into a leading immunology company. We will continue to look for ‘diamond in the rough’ opportunities,” added Dr. Lin.
About Aceriline
Aceriline is Los Angeles An area-based, late-stage, clinical biopharmaceutical company with additional operations in the San Francisco Bay Area focused on developing new, life-changing medicines for patients by accelerating the identification, acquisition, development and commercialization of promising drug candidates. We are focused on providing treatment options. For more information, please visit www.acelyrin.com.
Forward-Looking Statements
This press release describes the company’s ability to deliver treatments with clinically meaningful and differentiated benefits, addressable market opportunities for various product candidates in its pipeline, and execution of its goals to win and accelerate development. may contain forward-looking statements, including statements regarding the ability to the number of product candidates and the ability to profit from the ValenzaBio acquisition; Although ACELYRIN, INC. believes that all forecasts are based on reasonable assumptions, these forward-looking statements are subject to a number of risks and uncertainties that could lead to may differ materially from those anticipated in such forward-looking statements.
Source Aceririn Co., Ltd.
